
Twice-Yearly Lenacapavir Injections Show 96% Effectiveness in HIV Prevention – Study
A study has revealed that twice-yearly injections of lenacapavir, an antiretroviral drug, could reduce the risk of HIV infection by 96%. Published in the New England Journal of Medicine, the research shows that this injection regimen outperforms the daily oral PrEP option, Truvada, in preventing HIV among at-risk individuals. The Phase 3 trial involved 3,265…